The views expressed by contributors are their own and not the view of The Hill

Anti-Competitive Drug Agreements Cost Consumers

by Iowa GOP Sen. Chuck Grassley - 02/05/07 12:44 PM ET

Recently, the dramatic increase in wheeling and dealing between brand name and generic pharmaceutical manufacturers has only ended up delaying the entry of less costly medicines in the marketplace, leaving the bill to the consumer. These deals also threaten the sustainability of federal health care programs, such as Medicare and Medicaid. It’s important that the Federal Trade Commission have as many tools as possible in its arsenal to protect the American public from these types of anti-competitive agreements.

Tags